Objectives: To evaluate the clinical behavior and histologic characteristics of metastatic carcinoid tumors to the ovary.
Methods: Retrospective chart review and histologic specimen analysis of all patients with pathologically confirmed metastatic carcinoid tumor to the ovaries seen at the H. Lee Moffitt Cancer Center.
Results: Seventeen patients with metastatic carcinoid tumors to the ovary were identified. The distal ileum was the site of origin among all patients with identifiable primary tumor. Fifteen patients (88%) had bilateral ovarian metastases. Other metastatic sites (in order of frequency) included liver, peritoneum breast and bone. Fifteen patients (88%) had elevated urinary 5-hydroxyindoleacetic acid (5-HIAA), indicating active serotonin secretion, and sixteen patients (94%) had radiotracer uptake on indium-111-pentetreotide scans. Five-year survival rate was 94%.
Conclusions: Metastatic carcinoid tumors to the ovary typically originate from distal ileal tumors and are nearly always bilateral. Synchronous metastases involve liver and peritoneal surfaces. Favorable survival rates may be associated with octretide treatment and cytoreductive surgery.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ygyno.2007.02.034 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Capecitabine and temozolomide or temozolomide alone in patients with atypical carcinoids.
Endocrine
January 2025
Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum - Università di Bologna, Bologna, Italy.
Background: Lung neuroendocrine neoplasms (NENs) represent about 20% of all lung cancers. Few therapeutic options are available for atypical carcinoids (ACs). Single-agent temozolomide (TEM) is active in lung NENs, but whether the addition of capecitabine (CAPTEM) is associated with improved outcomes, is unknown.
View Article and Find Full Text PDFA phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumors.
Oncologist
January 2025
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, United States.
Objectives: Well-differentiated neuroendocrine tumors (NET) are highly vascular tumors characterized by their expression of vascular endothelial growth factor (VEGF). This trial investigated the activity of ramucirumab, a monoclonal antibody that targets VEGF receptor-2 (VEGFR-2) and inhibits activity of VEGF, in combination with somatostatin analog therapy in patients (pts) with advanced extra-pancreatic NET.
Methods: We conducted a single-arm phase II trial enrolling pts with advanced, progressive extra-pancreatic NET.
Segmentectomies: 5-Year Experience Of A Center.
Port J Card Thorac Vasc Surg
October 2024
Thoracic Surgery Department - Hospital de Santa Marta, Centro Hospitalar Universitário Lisboa Central, Portugal.
Introduction: Segmental anatomical resections have been a subject of debate in recent years. There is increasing evidence that these procedures may offer some advantages in the treatment of early-stage lung cancer, with overall survival (OS) and disease-free survival (DFS) similar to those seen in lobar anatomical resections.
Materials And Methods: We conducted a retrospective analysis of patients who underwent segmentectomy at Santa Marta Hospital (HSM) between January 2018 and September 2022.
Selecting systemic treatment for metastatic neuroendocrine tumors of the lung-current evidence and clinical implications.
Cancer Treat Rev
December 2024
Department of Medicine I, Division of Oncology, Medical University of Vienna, Austria. Electronic address:
Neuroendocrine tumors (NET) of the lung are a slowly growing subtype of lung cancer that has a different treatment paradigm than aggressive and more common forms of lung neuroendocrine neoplasms (NEN) like small cell lung cancer (SCLC). Current guidelines for metastatic lung NET advocate a handful of treatment options, including somatostatin analogs (SSA), everolimus, temozolomide- or platin-based chemotherapy, and peptide receptor radionuclide therapy (PRRT). However, there is no clear treatment sequence, and the therapy of choice may depend on several factors such as tumor grade / growth rate, tumor burden / symptoms, disease progression status, and somatostatin receptor (SSTR) expression.
View Article and Find Full Text PDFManagement of choroidal/ciliary body metastasis in the era of targeted cancer therapy.
Front Oncol
December 2024
Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, IA, United States.
Introduction: Choroidal metastases from systemic malignancies are the most common intraocular malignancies in adults. External beam radiation (EBR) has historically been first-line therapy for metastatic tumors to the choroid. However, good responses have been described with newer targeted biologics.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!